Charles River and Distributed Bio Enter Exclusive Partnership to Create an Integrated Antibody Discovery and Development Platform

October 25th 2018 | South San Francisco CA - full press release

RNZ: Covid treatment study shows promising results in hamsters

A potential treatment for covid-19 is a step closer to reality with a promising study involving hamsters showing a 97% reduction of coronavirus in lungs within 48 hours of treatment. Dr Jacob Glanville head of US company Distributed Bio has been working on the development of an anti-body treatment with the aim to begin trials with humans around September. He spoke to me about how his technology works, and what the success of the hamster trial means. Listen to the episode here

Featured Posts
Recent Posts
Archive
Search By Tags
Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square

(415) 489-0246

201 Gateway Blvd, Floor 1

 South San Francisco, CA 94080, USA